Press Releases

Date Title and Summary
Toggle Summary Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
Patients on trilaciclib received more chemotherapy cycles than those in the control arm Trilaciclib showed multi-lineage myelopreservation benefits when adjusting for longer duration of treatment Safety profile consistent with previously reported trials; no trilaciclib-related serious adverse
Toggle Summary G1 Therapeutics Announces Positive Myelopreservation Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq® in First-Line Small Cell Lung Cancer
Second randomized, double-blind, placebo-controlled Phase 2 trial confirms multi-lineage myelopreservation benefits of trilaciclib in first-line small cell lung cancer (1L SCLC) Statistically significant improvements in both primary endpoints of occurrence of Grade 4 neutropenia and duration of
Toggle Summary G1 Therapeutics to Present Preliminary Data from Randomized Phase 2 Trial of Trilaciclib in Metastatic Triple-Negative Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
RESEARCH TRIANGLE PARK, N.C. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that preliminary data from its randomized Phase 2 clinical trial of trilaciclib in combination with chemotherapy for the treatment of metastatic
Toggle Summary G1 Therapeutics Reports Third Quarter 2018 Financial Results and Corporate Update
Positive data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer presented at ESMO 2018 highlight myelopreservation and immune system benefits of trilaciclib Preliminary data from three additional randomized Phase 2 clinical trials of trilaciclib expected by
Toggle Summary G1 Therapeutics to Present at Investor Conferences in November 2018
RESEARCH TRIANGLE PARK, N.C. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca , M.D., Ph.D., will provide a company overview at the following upcoming investor conferences in
Toggle Summary G1 Therapeutics to Provide Third Quarter 2018 Corporate and Financial Update on November 7, 2018
RESEARCH TRIANGLE PARK, N.C. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2018 on Wednesday, November
Toggle Summary G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer
New data analyses highlight myelopreservation and immune system benefits of trilaciclib in combination with chemotherapy Data presented at the European Society for Medical Oncology ( ESMO ) 2018 Congress RESEARCH TRIANGLE PARK, N.C. , Oct. 21, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc.
Toggle Summary G1 Therapeutics to Present Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress
New data analyses demonstrate multi-lineage benefits of trilaciclib on neutrophils, red blood cells and lymphocytes in treatment of first-line small cell lung cancer RESEARCH TRIANGLE PARK, N.C. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc.
Toggle Summary G1 Therapeutics Announces Closing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the closing of an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $60.00 per share, including
Toggle Summary G1 Therapeutics Announces Pricing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $60.00 per share, for total
Toggle Summary G1 Therapeutics Announces Proposed Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares in the offering will be sold by
Toggle Summary G1 Therapeutics to Report Myelopreservation Data from Randomized Phase 2 Trial of Trilaciclib/Chemotherapy/Tecentriq® in Small Cell Lung Cancer in Fourth Quarter 2018
Management to host webcast and conference call today at 8:30 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it is expediting analyses of myelopreservation data from its
Toggle Summary G1 Therapeutics Announces Appointment of Garry Nicholson to Board of Directors
RESEARCH TRIANGLE PARK, N.C. , Sept. 13, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Garry Nicholson has been appointed to its board of directors, effective September 12, 2018 . “We are pleased to welcome Garry as an
Toggle Summary G1 Therapeutics to Present at H.C. Wainwright Investment Conference on September 5, 2018
RESEARCH TRIANGLE PARK, N.C. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Buck Phillips , Chief Financial Officer and Senior Vice President, Corporate Development will present a company overview at the following
Toggle Summary G1 Therapeutics Provides Second Quarter 2018 Corporate and Financial Update
Presenting additional data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer at ESMO 2018 in October   Initiated Phase 2a enrollment of lerociclib (G1T38) in ER+, HER2- breast cancer; positive Phase 1b data presented at ASCO 2018   Management to host
Toggle Summary G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 14, 2018
RESEARCH TRIANGLE PARK, N.C. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik, M.D., will present a company overview at the following investor conference: Wedbush PacGrow Healthcare
Toggle Summary G1 Therapeutics to Provide Second Quarter 2018 Corporate and Financial Update on August 8, 2018
RESEARCH TRIANGLE PARK, N.C. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2018 on Wednesday, August
Toggle Summary G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel
RESEARCH TRIANGLE PARK, N.C. , July 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth.
Toggle Summary G1 Therapeutics Announces Appointment of New Members to the Board of Directors
RESEARCH TRIANGLE PARK, N.C. , June 08, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Cynthia Schwalm and Willie Deese have been appointed to its board of directors, effective June 7, 2018 .
Toggle Summary G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
RESEARCH TRIANGLE PARK, N.C. , June 02, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 in combination with Faslodex ® (fulvestrant) showed promising safety,
Toggle Summary G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
RESEARCH TRIANGLE PARK, N.C. , May 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 in combination with Faslodex ® (fulvestrant) will be presented in a poster
Toggle Summary G1 Therapeutics Provides First Quarter 2018 Corporate and Financial Update
U.S. and European regulatory meetings scheduled based on positive trilaciclib Phase 2a myelopreservation data Preliminary data from G1T38 Phase 1b trial in breast cancer to be presented at ASCO on June 2 Management to host webcast and conference call today at 4:30 p.m.
Toggle Summary G1 Therapeutics to Present at UBS Global Healthcare Conference in May 2018
RESEARCH TRIANGLE PARK, N.C. , May 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca , M.D., Ph.D., will present a company overview at the following investor conference: UBS Global
Toggle Summary G1 Therapeutics to Provide First Quarter 2018 Corporate and Financial Update on May 3, 2018
RESEARCH TRIANGLE PARK, N.C. , April 26, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced it will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2018 on Thursday, May 3 at 4:30
Toggle Summary G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
RESEARCH TRIANGLE PARK, N.C. , April 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38, its oral CDK4/6 inhibitor, in combination with Tagrisso ® (osimertinib) in
Toggle Summary G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitors Trilaciclib and G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting
RESEARCH TRIANGLE PARK, N.C. , April 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preclinical data on both of the company’s CDK4/6 inhibitors will be presented at the 2018 American Association for Cancer Research Annual
Toggle Summary G1 Therapeutics Announces Closing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 12, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the closing of an underwritten public offering of 3,910,000 shares of its common stock at a public offering price of $29.50 , including 510,000
Toggle Summary G1 Therapeutics Announces Pricing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 07, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,400,000 shares of its common stock at a public offering price of $29.50 , for total gross
Toggle Summary G1 Therapeutics Announces Proposed Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 05, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares in the offering will be sold by
Toggle Summary G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits in Patients with Small Cell Lung Cancer
Statistically significant results highlight benefit of trilaciclib in several prospectively-defined parameters, including: Grade 4 neutropenia, G-CSF usage, and chemotherapy dose reductions and delays Clinically meaningful data favoring trilaciclib versus placebo, including: febrile neutropenia,
Toggle Summary G1 Therapeutics to Present at Investor Conferences in March 2018
RESEARCH TRIANGLE PARK, N.C. , March 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca , M.D., Ph.D., will present a company overview at the following upcoming investor conferences in March:
Toggle Summary G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights
Topline data expected in March 2018 from first of three ongoing Phase 2 trials evaluating the myelopreservation benefits of trilaciclib Management to host webcast and conference call today at 4:30 p.m. EST RESEARCH TRIANGLE PARK, N.C. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc.
Toggle Summary G1 Therapeutics to Report Fourth Quarter and Full-Year 2017 Financial Results on February 21, 2018
RESEARCH TRIANGLE PARK, N.C. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that fourth quarter and full-year 2017 financial results will be reported on Wednesday, February 21, 2018 , after the close of U.S.
Toggle Summary G1 Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca , M.D., Ph.D., will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference .
Toggle Summary G1 Therapeutics Added to Nasdaq Biotechnology Index
RESEARCH TRIANGLE PARK, N.C. , Dec. 18, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI), effective prior to market open on Monday, December 18, 2017
Toggle Summary G1 Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C. , Dec. 06, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the grant of an equity inducement award to Barclay (Buck) Phillips , who joined the Company as Chief Financial Officer and Senior Vice President,
Toggle Summary G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer
Phase 1b/2 study evaluating AstraZeneca’s Tagrisso® and G1T38 in EGFR mutation-positive non-small cell lung cancer is expected to initiate in the first quarter of 2018 RESEARCH TRIANGLE PARK, N.C. , Nov. 28, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc.
Toggle Summary G1 Therapeutics Reports Third Quarter 2017 Financial Results and Recent Operational Highlights
Barclay Phillips appointed Chief Financial Officer and SVP, Corporate Development Management reaffirms expectation of topline data from Phase 2a trial of trilaciclib in first-line small-cell lung cancer in first quarter 2018 RESEARCH TRIANGLE PARK, N.C. , Nov.
Toggle Summary G1 Therapeutics Makes Key Executive Appointments
Barclay Phillips appointed Chief Financial Officer and Senior Vice President, Corporate Development Chandra Lovejoy named Vice President, Global Regulatory Affairs RESEARCH TRIANGLE PARK, N.C. , Nov. 08, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology
Toggle Summary G1 Therapeutics to Present at Stifel 2017 Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca , MD, PhD, will present a company overview at the Stifel 2017 Healthcare Conference.
Toggle Summary G1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell Response
Intermittent dosing of G1’s CDK4/6 inhibitor trilaciclib enhances anti-tumor efficacy of checkpoint inhibitors in preclinical models RESEARCH TRIANGLE PARK, N.C. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, announced the publication “
Toggle Summary G1 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
RESEARCH TRIANGLE PARK, N.C. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective after market close on September 15, 2017 ,
Toggle Summary G1 Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights
Completed enrollment of Phase 2a small-cell lung cancer trial, with topline data expected in first quarter 2018 Closed initial public offering that raised $107.1 million in net proceeds RESEARCH TRIANGLE PARK, N.C. , Aug. 09, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc.
Toggle Summary G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca , MD, PhD, will present a company overview at the Wedbush PacGrow Healthcare Conference .
Toggle Summary G1 Therapeutics Makes Key Appointments to Management Team
Terry Murdock appointed Senior Vice President, Development Operations Shannon Morris , MD, PhD, named Vice President, Clinical Development RESEARCH TRIANGLE PARK, N.C. , Aug. 03, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the
Toggle Summary G1 Therapeutics to Ring Nasdaq Stock Market Closing Bell on Wednesday, August 2, 2017
RESEARCH TRIANGLE PARK, N.C. , July 27, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that the Company will ring the Nasdaq Stock Market Closing Bell on Wednesday, August 2, 2017 , at 4 p.m.
Toggle Summary G1 Therapeutics Appoints Sir Andrew Witty to Board of Directors
RESEARCH TRIANGLE PARK, N.C. , July 13, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the appointment of Sir Andrew Witty to its board of directors. “We are thrilled to welcome Andrew to our board of directors,” said Mark Velleca ,
Toggle Summary G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting
RESEARCH TRIANGLE PARK, N.C. , May 30, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor trilaciclib as a first-line combination treatment in patients
Toggle Summary G1 Therapeutics Announces Closing of Initial Public Offering
RESEARCH TRIANGLE PARK, N.C. , May 23, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the closing of its initial public offering of 7,781,564 shares of common stock at a public offering price of $15.00 per share, including 781,564
Toggle Summary G1 Therapeutics Announces Pricing of Initial Public Offering
RESEARCH TRIANGLE PARK, N.C. , May 16, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. , a clinical-stage oncology company, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of
Toggle Summary G1 Therapeutics Announces Launch of Initial Public Offering
RESEARCH TRIANGLE PARK, N.C. , May 08, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (“G1” or the “Company”), a clinical-stage oncology company, today announced the commencement of the initial public offering of shares of its common stock pursuant to a registration statement on Form S-1 filed with
Toggle Summary G1 Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting
RESEARCH TRIANGLE PARK, NC – March 29, 2017 – G1 Therapeutics, Inc. , a clinical-stage oncology company, announced today that it will present preclinical data on trilaciclib, G1T38, and G1T48 at the 2017 American Association for Cancer Research (AACR) Annual Meeting, to be held April 1-5 in
Toggle Summary G1 Therapeutics Initiates Three Drug Development Programs in Breast Cancer
Phase 2 trial of trilaciclib in triple-negative breast cancer Phase 1b/2a trial of G1T38 in estrogen receptor-positive breast cancer Oral SERD (G1T48) in IND-enabling studies; Phase 1 trial planned for 4Q17 RESEARCH TRIANGLE PARK, NC – January 10, 2017 – G1 Therapeutics, Inc.
Toggle Summary G1 Therapeutics to Present at 35th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, NC – January 3, 2017 – G1 Therapeutics, Inc. , a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference.
Toggle Summary G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer
Phase 2 study evaluating potential of Genentech's Tecentriq plus trilaciclib and chemotherapy as a first-line treatment for small-cell lung cancer patients expected to begin in first half of 2017 s RESEARCH TRIANGLE PARK, NC, December 5, 2016 – G1 Therapeutics, Inc.
Toggle Summary G1 Therapeutics to Present Positive Clinical and Preclinical Data on CDK4/6 Inhibitor G1T28 at December Scientific Conferences
RESEARCH TRIANGLE PARK, NC, November 21, 2016 – G1 Therapeutics, Inc ., a clinical-stage oncology company, announced today that preliminary clinical data from its lead CDK4/6 inhibitor G1T28 for patients with small-cell lung cancer (SCLC) will be presented at the International Association for the
Toggle Summary G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference
RESEARCH TRIANGLE PARK, NC, August 10, 2016 – G1 Therapeutics, Inc ., a clinical-stage oncology company, announced today that Chief Medical Officer Raj Malik, MD, will present a company overview at the Wedbush PacGrow Healthcare Conference. The presentation will take place on Wednesday, August 17,
Toggle Summary G1 Therapeutics Secures $47 Million Series C Financing
Proceeds will advance lead CDK4/6 inhibitors through early and mid-stage clinical trials, expand pipeline in multiple oncology indications RESEARCH TRIANGLE PARK, NC, May 11, 2016 – G1 Therapeutics, Inc ., a clinical-stage oncology company, announced today the completion of a $47 million Series C
Toggle Summary G1 Therapeutics to Present Clinical and Preclinical Data on CDK4/6 Inhibitors G1T28 and G1T38 at the 2016 American Association for Cancer Research Annual Meeting
Preliminary clinical data on G1T28 in combination with chemotherapy in newly diagnosed small-cell lung cancer patients Preclinical data on potential best-in-class oral CDK4/6 inhibitor G1T38 RESEARCH TRIANGLE PARK, NC, April 15, 2016 – G1 Therapeutics, Inc ., a clinical-stage oncology company,
Toggle Summary G1 Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
RESEARCH TRIANGLE PARK, NC, February 2, 2016 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the 18th Annual BIO CEO & Investor Conference.
Toggle Summary G1 Therapeutics to Present at the Stifel 2015 Healthcare Conference
RESEARCH TRIANGLE PARK, NC, November 10, 2015 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the Stifel 2015 Healthcare Conference on Tuesday, November 17 at 10:15 a.m.
Toggle Summary Glenn P. Muir Appointed to G1 Therapeutics Board of Directors
RESEARCH TRIANGLE PARK, NC, October 21, 2015 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today the appointment of Glenn P. Muir, CPA, to its board of directors. "Glenn has been a key architect in the formation and implementation of strategic financial initiatives at global
Toggle Summary G1 Therapeutics to Present at September Biotech Conferences
RESEARCH TRIANGLE PARK, NC, September 3, 2015 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present at two biotech conferences in September. 22nd Annual NewsMakers in the Biotech Industry Location: Millennium
Toggle Summary G1 Therapeutics Announces Initiation of Two Phase 1b/2a Trials of CDK4/6 Inhibitor G1T28 in Small-Cell Lung Cancer
Trials will assess G1T28 as a bone marrow and immune system chemoprotectant in newly diagnosed and previously treated patients with small-cell lung cancer G1T28 was well-tolerated and demonstrated robust, reversible, G1 cell cycle arrest of bone marrow stem cells in a Phase 1a trial RESEARCH PARK
Toggle Summary G1 Therapeutics to Present at August Investor Conferences
RESEARCH TRIANGLE PARK, NC, August 5, 2015 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that that senior management will be presenting at two investor conferences on August 12. Canaccord Genuity Growth Conference Location : InterContinental Boston, Boston, MA
Toggle Summary G1 Therapeutics to Present at the BIO International Convention
RESEARCH TRIANGLE PARK, NC, June 10, 2015 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Business Officer Greg Mossinghoff will present a company overview at the BIO International Convention on Wednesday, June 17 at the Pennsylvania Convention Center in
Toggle Summary G1 Therapeutics Announces Positive Phase 1a Data for CDK4/6 Inhibitor G1T28
G1T28 produced robust, transient, G1 cell cycle arrest of bone marrow cells Compound was well tolerated with predictable pharmacokinetic / pharmacodynamic activity Data support advancement into two Phase 1b/2a studies in patients with small-cell lung cancer RESEARCH TRIANGLE PARK, NC, May 27, 2015
Toggle Summary G1 Therapeutics to Present New Data on CDK4/6 Inhibitor G1T28 at the American Association for Cancer Research Annual Meeting
G1T28 induces transient arrest of bone marrow stem cells, protecting animals from chemotherapy-induced myelosuppression RESEARCH TRIANGLE PARK, NC, April 15, 2015 – G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs
Toggle Summary G1 Therapeutics to Present at the 14th Annual Needham Healthcare Conference
RESEARCH TRIANGLE PARK, NC, April 8, 2015 – G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the
Toggle Summary G1 Therapeutics to Present at 22nd Annual Future Leaders in the Biotech Industry Conference
RESEARCH TRIANGLE PARK, NC, March 16, 2015 – G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the
Toggle Summary G1 Therapeutics Raises $33 Million in Series B Financing
Proceeds to accelerate clinical development of lead CDK4/6 inhibitor for antineoplastic and chemoprotection indications Fred Eshelman and Peter Kolchinsky join board of directors RESEARCH TRIANGLE PARK, NC, February 5, 2015 – G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing
Toggle Summary G1 Therapeutics to Present at 17th Annual BIO CEO & Investor Conference
RESEARCH TRIANGLE PARK, NC, February 2, 2015 – G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology, today announced that Chief Executive Officer Mark Velleca, MD, PhD, will provide a corporate overview at
Toggle Summary G1 Therapeutics Initiates Phase 1 Clinical Trial of G1T28-1
Lead drug candidate is a highly potent and selective CDK4/6 inhibitor Data expected by early 2015 Initiation of Phase 1b/2a trial in oncology patients expected in second quarter of 2015 RESEARCH PARK TRIANGLE, NC, September 10, 2014 – G1 Therapeutics, Inc., a privately held, clinical-stage
Toggle Summary G1 Therapeutics Profiled in Xconomy
Toggle Summary G1 Therapeutics Profiled in Start-Up
Toggle Summary G1 Therapeutics Completes Leadership Team with Appointment of Raj Malik, MD, Chief Medical Officer and Greg Mossinghoff, Chief Business Officer
Team advancing G1's lead CDK4/6 inhibitor toward Phase I clinical trials in third quarter RESEARCH PARK TRIANGLE, NC, June 17, 2014 – G1 Therapeutics, Inc., a privately held pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and
Toggle Summary G1 Therapeutics Appoints Dr. Mark Velleca as Chief Executive Officer
Management team strengthened as company advances lead product candidate Biopharmaceutical executive, physician and scientist brings diverse expertise and oncology experience Research Triangle Park, NC, May 20, 2014 – G1 Therapeutics, Inc., a privately held pharmaceutical company that focuses on the
Toggle Summary G1 Therapeutics to Share New Research Findings at AACR Annual Meeting 2014
Robust antitumor activity of G1's novel CDK4/6 inhibitors to be highlighted in poster on April 7 Chapel Hill, NC, March 27, 2014 – G1 Therapeutics, Inc., a privately held pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and